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ABSTRACT Vaccination with pneumococcal conjugate vaccines (PCVs) disrupts the
pneumococcal population. Our aim was to determine the impact of the 10-valent
PCV on the serotypes, genetic lineages, and antimicrobial susceptibility of pneumo-
cocci isolated from children in Iceland. Pneumococci were collected between 2009
and 2017 from the nasopharynges of healthy children attending 15 day care centers
and from the middle ears (MEs) of children with acute otitis media from the greater
Reykjavik capital area. Isolates were serotyped and tested for antimicrobial suscepti-
bility. Whole-genome sequencing (WGS) was performed on alternate isolates from
2009 to 2014, and serotypes and multilocus sequence types (STs) were extracted
from the WGS data. Two study periods were defined: 2009 to 2011 (PreVac) and
2012 to 2017 (PostVac). The overall nasopharyngeal carriage rate was similar be-
tween the two periods (67.3% PreVac and 61.5% PostVac, P  0.090). Vaccine-type
(VT) pneumococci decreased and nonvaccine-type (NVT) pneumococci (serotypes 6C,
15A, 15B/C, 21, 22F, 23A, 23B, 35F, and 35B) significantly increased in different age
strata post-PCV introduction. The total number of pneumococci recovered from ME
samples significantly decreased as did the proportion that were VTs, although NVT
pneumococci (6C, 15B/C, 23A, and 23B) increased significantly. Most serotype 6C
pneumococci were multidrug resistant (MDR). Serotype 19F was the predominant se-
rotype associated with MEs, and it significantly decreased post-PCV introduction:
these isolates were predominantly MDR and of the Taiwan19F-14 PMEN lineage.
Overall, the nasopharyngeal carriage rate remained constant and the number of
ME-associated pneumococci decreased significantly post-PCV introduction; however,
there was a concomitant and statistically significant shift from VTs to NVTs in both
collections of pneumococci.
KEYWORDS Iceland, Streptococcus pneumoniae, carriage, epidemiology, molecular
epidemiology, otitis media, pneumococcus, vaccination, vaccine
Streptococcus pneumoniae is an important human pathogen that can cause relativelymild upper respiratory tract infections, such as acute otitis media (AOM), or more
severe infections, such as pneumonia and invasive pneumococcal disease (IPD) (1).
Pneumococci frequently colonize the nasopharynges of humans, especially children
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attending day care centers (DCCs) (2, 3), and asymptomatic carriage occurs at least once
prior to the age of 2 years (4). Nasopharyngeal colonization precedes pneumococcal
disease, is a major factor for horizontal transmission within the community, especially
among young children (5), and reflects the pneumococcal strains circulating in the
community (6). Pneumococci are among the most frequent causes of bacterial AOM
(7–9), which is the most common bacterial infection in children under 3 years of age
(10). Pneumococcal conjugate vaccines (PCVs) interrupt the transmission of antibiotic-
resistant pneumococci and thus decrease the burden of disease caused by antibiotic-
resistant isolates in immunized children. Therefore, studies of the impact of these
vaccines on antibiotic resistance and serotype distribution should focus both on
pneumococci from nasopharyngeal carriage and from middle ears of children of similar
ages with AOM (11).
Current PCVs target only a limited number of serotypes, especially those commonly
causing IPD in young children (12–14). PCVs have been implemented in the infant
vaccine immunization program in over 100 countries (15), which has resulted in a
decrease of IPD caused by vaccine serotypes (VTs) in vaccinated children and other age
groups due to herd immunity (16–18). Among healthy children, PCV implementation
has also resulted in serotype replacement in carriage where VTs have been replaced
with nonvaccine serotypes, meaning that the total carriage rate has remained constant
(19–21). Pneumococcal carriage has been monitored and recorded in Iceland for the
past 2 decades (22–24). The carriage rates have been consistent over time, ranging from
50% to 70% in healthy preschool children 1 to 7 years of age (25). The 10-valent PCV
(PHiD-CV [Synflorix; GSK]), which directly targets 10 serotypes, was introduced into the
national pediatric immunization program in Iceland in April 2011 in a 2-plus-1 schedule
without catch-up. No other pneumococcal vaccine was previously included. The aim of
this study was to assess the impact of PHiD-CV on the distribution of pneumococcal
serotypes and genetic lineages among pneumococci from the nasopharynges of
healthy children and the middle ears of children with otitis media and assess any
changes in antimicrobial resistance rates after vaccine implementation.
MATERIALS AND METHODS
DCC study and bacterial isolates. Nasopharyngeal swabs were taken from healthy children 1 to 7
years of age in March every year from 2009 to 2017 after informed consent was obtained from the
parents. The children were attending 15 DCCs, chosen to be representative of the greater Reykjavík area.
The period 2009 to 2011 was defined as the prevaccination period (PreVac), and the years 2012 to 2017
were the postvaccine implementation period (PostVac). The number of nasopharyngeal swabs taken
from each age group is listed in Table S1 in the supplemental material. The samples were selectively
cultured for pneumococci on blood agar containing 5 g/ml gentamicin and incubated anaerobically
(26). Very few children attended public DCCs before the age of 12 months, and no children 1 year of
age were sampled in this study.
Middle ear study and bacterial isolates. All pneumococci isolated from middle ear (ME) samples
from children 0 to 7 years of age with otitis media submitted to the Department of Clinical Microbi-
ology, Landspitali University Hospital, between 1 January 2009 and 30 September 2017 were included in
this study. This is the primary microbiology laboratory for the greater Reykjavík capital area. It provides
services for individuals from the rural area and visiting specialists in the capital, and it is the reference
laboratory for the whole country (approximately 85% of the population for ME samples).
The primary service area for the Landspitali University Hospital was considered to be within 100 km
driving distance from the hospital, and the population demographic information for this referral region
was obtained from Statistics Iceland (www.statice.is). The average population sizes for children 0 to 7
years of age in the referral region during the study period were 23,747 children PreVac and 24,083
children PostVac (approximately 66% of all children in Iceland 0 to 7 years of age). A detailed listing
of the populations according to age groups can be seen in Table S2. When two or more pneumococcal
isolates of the same phenotype were identified from the same patient within 30 days, only one isolate
was included in the analyses.
Serotyping. Serotypes were determined for all available isolates with the Immulex pool antisera
(State Serum Institute, Copenhagen, Denmark) and/or by multiplex PCR (mPCR), according to previously
published methods (27–30). The mPCR scheme included 78 sets of serogroup/serotype-specific primer
pairs and two primer pairs for a positive internal control: cpsA for the capsular locus and lytA for autolysin.
Serotypes of serogroup 6 were identified using previously described PCR methods (31–33). Nontypeable
(nonencapsulated S. pneumoniae [NESp]) isolates, i.e., those that were negative for cpsA and positive for
lytA, were tested for the cpsB gene, which is essential for capsulation (34), according to a previously
published PCR method (35). For those pneumococcal genomes that were sequenced, seqSerotyper
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(https://github.com/avantonder/seqSerotyper) was used to extract the serotypes from sequence data
(36).
DNA extraction and whole-genome sequencing. Every other pneumococcal isolate from naso-
pharyngeal and ME samples from the period 2009 to 2014 was selected for whole-genome sequencing
(WGS). DNA was extracted using the Promega Maxwell 16 platform, and the DNA extracts were
sequenced on the Illumina HiSeq 2000. WGS data were assembled using Velvet (37) before SSPACE and
GapFiller were used to improve the assemblies and close gaps (38, 39). The final assembled genomes
were uploaded into a Bacterial Isolate Genome Sequence Database (BIGSdb) along with associated
metadata (40). The multilocus sequence type (ST) of each isolate was extracted from the WGS data using
BIGSdb and the PubMLST database (http://pubmlst.org/spneumoniae/). STs were assigned to clonal
complexes (CCs) via Phyloviz (41).
Genomic analyses. Prokka was used to predict the coding sequences in each genome (42). The
resulting annotation files in gff format were then used as the input for Roary and clustered using a
sequence identity threshold of 90% (43). The core genome was estimated using a Bayesian core genome
model and a threshold of 99.9% for nasopharyngeal isolates and 99.8% for ME isolates (44). The core
genes in both sample groups were extracted and aligned using MAFFT (45). FastTree was used to
construct phylogenetic trees, and ClonalFrameML (46) was used to reconstruct the trees to account for
recombination. The final phylogenetic trees were then annotated using iTOL (47).
Antibiotic susceptibility testing. All isolates were tested for antimicrobial susceptibility to chlor-
amphenicol, erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and clindamycin by disk diffu-
sion tests. Oxacillin disks (1 g) were used to screen for penicillin resistance; isolates susceptible to
oxacillin were considered to be susceptible to penicillin. For oxacillin-resistant isolates, the MICs to
penicillin and ceftriaxone (ME isolates only) were measured using the Etest (bioMérieux, France) (48).
Penicillin-nonsusceptible pneumococci (PNSP) were defined as isolates having a MIC of 0.06 mg/liter,
while resistant pneumococci were isolates having a MIC of 2 mg/liter. Multidrug resistance (MDR) was
defined as nonsusceptibility to three or more classes of antimicrobials (regardless of penicillin nonsus-
ceptibility). The susceptibility testing was performed according to the methods and criteria of the
European Committee on Antimicrobial Susceptibility Testing (EUCAST) (49).
Statistical analyses. A likelihood ratio test (50) was used to test the null hypothesis of equal rates
when comparing the rate (r1) of a certain serotype, CC, or ST in a given age group PreVac to the rate (r2)
of the same serotype, CC, or ST in the same age group PostVac. The test is based on the assumption that
the counts of the serotype, CC, or ST in the two periods are independent and both follow Poisson
distributions. It is assumed that the mean of the counts PreVac is equal to the rate r1 times the total
number of individuals in the age group PreVac. The mean of the counts PostVac is equal to the rate r2
times the total number of individuals in the age group PostVac. The asymptotic distribution of the
likelihood ratio test statistics is a chi-square distribution with one degree of freedom under the null
hypothesis. Microsoft Excel was used to calculate the test statistics and the corresponding P values.
The two-sided Fisher’s exact test was used to calculate the P values for antimicrobial resistance by
using the statistical software R, version 3.3.2. The level of significance for all tests was 0.05. The Simpson
diversity index was used to calculate the diversity of STs (51).
Ethics. The study was approved by The National Bioethics Committee (VSNb2013010015/03.07) and
the appropriate authorities at the Landspitali University Hospital and the day care centers.
RESULTS
Nasopharyngeal samples from children attending DCCs. A total of 4,461 naso-
pharyngeal swabs were collected (450 to 550 samples each year): 1,380 PreVac and
3,081 PostVac (Table 1). The median age of the children who were sampled was 4.1
years. The cultures yielded 3,029 pneumococcal isolates, and 250 children carried two
pneumococcal strains. Nine isolates were excluded (not viable/not stored), yielding
3,020 isolates: 991 (32.8%) PreVac and 2,029 (67.2%) PostVac. The carriage rates were
67.3% PreVac and 61.5% PostVac (P  0.090). Overall, 51.8% (n  1,563) of the isolates
were collected from children 4 to 7 years of age, and the fewest isolates, 3.5% (n 
103), were from the children 1 to 2 years of age (see Table S3 in the supplemental
material). The genomes of 987 (49.2%) pneumococcal isolates from 2009 to 2014 were
sequenced.
Serotypes. A total of 36 different serotypes were detected: 27 PreVac and 35
PostVac. Overall, the numbers of isolates of serotypes included in PHiD-CV (vaccine type
[VT]) decreased between the two periods (P  0.001) (Table 1). VT pneumococci were
most common in 2010 (171/324 [52.8%]) and least common in 2016 (5/354 [1.4%])
(Table 1). The numbers of isolates of serotypes not included in PHiD-CV (nonvaccine
type [NVT]) increased from PreVac (n  545, 395.2/1,000 samples) to PostVac (n 
1,725, 559.9/1,000 samples; P  0.001) (Table 1). NVT pneumococci were most common
in 2016 (349/354 [98.6%]) and least common in 2010 (153/324 [47.2%]) (Table 1).
In children 1 to 2 years of age, only one NVT, serotype 23A, increased from PreVac
(n  0, 0/1,000 samples) to PostVac (n  7, 95.9/1,000 samples; P  0.005). The NVTs
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that increased PostVac and were the most prevalent in children 2 to 4 years of age
were of serotypes 6C (n  82, 65.0/1,000 samples; P  0.001), 15B/C (n  81, 64.2/1,000
samples; P  0.001), and 23B (n  69, 54.7/1,000 samples; P  0.001) (Table S3).
The NVTs that increased PostVac in children 4 to 7 years of age were serotypes 23B
(n  80, 45.8/1,000 samples; P  0.001), 6C (n  56, 32.1/1,000 samples; P  0.001), and
21 (n  53, 30.4/1,000 samples; P  0.001). Serotype 23B was only detected PostVac
among children 4 to 7 years of age (Table S3).
MLST/CC. Among the 987 sequenced isolates, 47 CCs (35 CCs PreVac and 41 CCs
PostVac) and 104 STs (66 STs PreVac and 83 STs PostVac) were detected, and 12 CCs and
43 STs were unique to nasopharyngeal isolates. The Simpson diversity index of the STs
was 0.97 for both periods. A phylogenetic tree was created with the concatenated
sequences of 1,066 full-length coding loci found in 99.9% of the nasopharyngeal
TABLE 1 Serotype distribution each study year in nasopharyngeal samples among children 1 to 7 years old PreVac (2009 to 2011) and
PostVac (2012 to 2017)







(n/1,000 samples) P value2009 2010 2011 2012 2013 2014 2015 2016 2017 PreVac
3 18 26 24 11 13 20 32 25 12 68 49.3 113 36.7 0.052
4 2 0 0 0 0 0 0 0 0 2 1.4 0 0 0.096
6A 38 24 25 56 23 16 21 23 11 87 63.0 150 48.7 0.051
6B 50 45 14 17 16 26 9 1 2 109 79.0 71 23.0 0.001
6C 3 4 2 0 11 7 31 49 53 9 6.5 151 49.0 0.001
9V 12 3 3 1 0 0 0 0 0 18 13.0 1 0.3 0.001
9A 0 0 1 0 1 0 0 0 0 1 0.7 1 0.3 0.619
9N 6 0 3 3 4 6 5 1 0 9 6.5 19 6.2 0.873
10 0 0 0 0 0 0 3 5 0 0 0 8 2.6 0.052
10A 5 0 0 2 1 8 3 1 8 5 3.6 23 7.5 0.131
10B 0 0 0 0 0 7 0 0 0 0 0 7 2.3 0.075
11A 18 19 21 22 10 38 37 24 5 58 42.0 136 44.1 0.756
13 0 0 0 0 1 0 0 0 0 0 0 1 0.3 0.691
14 26 36 12 8 9 9 3 0 0 74 53.6 29 9.4 0.001
15 0 0 1 0 0 0 1 1 1 1 0.7 4 1.3 0.385
15A 0 0 0 0 0 1 14 11 9 0 0 35 11.4 0.001
15B/C 21 6 10 29 27 29 24 22 15 37 26.8 146 47.4 0.001
16F 3 8 13 3 2 4 5 5 6 24 17.4 25 8.1 0.008
17 0 0 0 0 0 0 1 0 0 0 0 1 0.3 0.691
18C 0 0 0 0 0 0 2 0 0 0 0 2 0.6 0.477
19 15 12 4 7 6 3 3 0 0 31 22.5 19 6.2 0.001
19F 30 28 29 22 28 21 13 3 0 87 63.0 87 28.2 0.001
19A 47 16 26 12 26 29 22 31 25 89 64.5 145 47.1 0.020
21 2 1 2 4 15 17 14 23 13 5 3.6 86 27.9 0.001
22F 3 2 2 3 17 31 4 9 5 7 5.1 69 22.4 0.001
23 0 0 0 0 0 0 1 2 1 0 0 4 1.3 0.227
23F 50 47 28 39 30 7 17 1 3 125 90.6 97 31.5 0.001
23A 12 10 7 6 22 24 16 35 6 29 21.0 109 35.4 0.009
23B 1 0 0 9 15 25 41 34 28 1 0.7 152 49.3 0.001
24F 0 0 0 0 0 0 0 0 4 0 0 4 1.3 0.227
29 3 0 0 2 0 0 0 0 0 3 2.2 2 0.6 0.210
31 2 0 0 0 0 0 0 1 5 2 1.4 6 1.9 0.765
33 2 2 1 4 2 4 0 1 0 5 3.6 11 3.6 0.954
33F 3 2 5 1 1 2 4 8 1 10 7.2 17 5.5 0.492
33_Hybrid 0 0 0 0 0 4 0 0 0 0 0 4 1.3 0.227
35F 0 0 0 3 15 18 16 4 0 0 0 56 18.2 0.001
35B 1 1 4 0 17 12 13 2 13 6 4.3 57 18.5 0.001
38 0 9 10 2 5 3 3 1 3 19 12.8 17 5.5 0.007
Other serotypesa 0 1 1 0 1 1 11 17 19 2 1.4 49 15.9 0.001
NESpb 21 22 25 18 16 22 22 14 24 68 49.3 116 37.7 0.075
Total 394 324 273 284 334 394 391 354 272 991 718.1 2,029 658.6 0.001
VTc 185 171 90 94 89 66 45 5 5 446 323.2 304 98.7 0.001
NVTd 209 153 183 190 245 328 346 349 267 545 394.9 1,725 559.9 0.001
All NPe samples 516 444 420 465 471 566 533 540 506 1380 3,081
Samples of positive Pnf (%) 76.4 73.0 65.0 61.1 70.9 69.6 73.4 65.6 53.8 71.8 65.9
aSerotypes other than those included in the multiplex PCR panel of the study.
bNESp, nonencapsulated S. pneumoniae.
cSerotypes detected in the study that are included in PHiD-CV (4, 6B, 9V, 14, 18C, 19F, and 23F).
dSerotypes that are not included in PHiD-CV.
eNP, nasopharyngeal samples.
fPn, pneumococci.
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carriage pneumococcal genomes. The tree was annotated with CC designations and
serotypes (Fig. 1).
CC43923F/A/B was the most common CC in both study periods. Initially, 77.6% of the
isolates of CC43923F/A/B were VT serotype 23F, but PostVac, 42.0% were NVT serotype
23B; however, serotype 23B was rare prior to vaccine introduction (Fig. 1 and Table S4).
Between the two periods, the prevalence of CC43322F increased from two isolates
(1.5/1,000 samples) to 30 (20.0/1,000 samples; P  0.001) (Fig. 1 and Table S4), and
similarly, CC126215B/C increased from three isolates (2.2/1,000 samples) to 18 (12.0/
1,000 samples; P  0.032) (Fig. 1 and Table S4).
Antimicrobial resistance. The overall prevalence of PNSP among nasopharyngeal
isolates did not change significantly between the two study periods: 15.0% (n 
149/991) versus 16.7% (338/2,029; P  0.268) (Table 2). Erythromycin-resistant pneu-
mococci decreased from 17.6% to 13.7% (P  0.007). The overall prevalence of MDR
pneumococci decreased slightly but significantly between the periods, from 15.2%
(n  151/991) to 12.4% (n  251/2,029; P  0.030) (Table 2). Before PHiD-CV was
introduced, 85.2% of PNSP pneumococci were also MDR, and this was reduced to 70.1%
(P  0.001). The most prevalent PNSP and MDR isolates were of serotype 19F PreVac
and NESp PostVac (Table 2).
Among the PNSP serotype 19F isolates, 92.5% belonged to CC236/271/32019F (Fig.
1 and Table S4). Serotype 19A PNSP increased from 4.0% to 10.4% of isolates (P 
0.021) (Table 2), and the isolates were predominantly members of CC19919A,15B/C (Fig.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIG 1 Phylogenetic tree created from 1,066 full-length coding loci found in 99.9% of 987 genomes from carriage samples and annotated with CC designations.
Serotypes (inner circle) and study periods (outer circle) are also presented.
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Serotype 6C belonged to CC3156B/C. Serotype 35B PNSP were only detected after
vaccine introduction, and they were members of CC19835B, which was not previously
detected in carriage (Table 2, Fig. 1, and Table S4). The proportion of MDR NESp isolates
increased between the two study periods from 23.2% to 33.9% (P  0.025) (Table 2),
and 82.4% of MDR NESp PostVac isolates were members of CC344NT (Fig. 1 and
Table S4).
Middle ear samples from AOM. The Department of Clinical Microbiology received
6,651 ME samples during the study period. The total annual number of ME samples
decreased from 966 samples in 2009 to 421 by the end of September 2017 (Table 3).
Among all 6,651 samples, 994 were positive for pneumococci and 18 isolates were
excluded, as they were not stored or not viable, leaving a total of 976 isolates for further
analysis. The annual number of pneumococcal isolates from ME decreased from 197
(8.5/1,000 children aged 0 to 7 years) in 2009 to 44 (1.9/1,000 children) in 2016, and
by the end of September 2017, the number of isolates was 23 (1.0/1,000 children) (Table
3). The median age of the children from which the ME isolates were obtained was 1.5
years, and 69.1% (n  674) of the isolates were collected from the youngest age group
(0 to 2 years of age). The average annual number of isolates in the youngest age
group (0 to 2 years) decreased from 133.7 (18.1/1,000 children aged 0 to 2 years per
year) PreVac to 45.5 (6.9/1,000 children aged 0 to 2 years per year) PostVac (P  0.020)
(see Table S5). The genomes of 441 (50.6%) pneumococcal isolates from 2009 to 2014
were sequenced.
Serotypes. Overall, 894/976 (91.6%) pneumococcal isolates from ME samples were
successfully serotyped, but 82 isolates (8.4%) were of serotypes other than those
included in the mPCR scheme. Twenty-eight serotypes were detected overall: 23 PreVac
and 22 PostVac. The numbers of VT pneumococci decreased significantly between the
two periods (P  0.001) (Table 3). The numbers of VT pneumococci decreased signif-
icantly in the two younger age groups (children 0 to 2 years, P  0.001; and 2 to 4
years of age, P  0.005), while there was no change between the periods for the oldest
age group (children 4 to 7 years of age; P  0.450) (Table S5).
The NVT pneumococci that increased PostVac in children aged 0 to 2 years were
serotypes 15B/C (n  1 to n  40; P  0.001), 6C (n  1 to n  29; P  0.001), 23A
(n  2 to n  18; P  0.007), and 23B (n  1 to n  10; P  0.042). Serotype 15B/C was
the only NVT that increased in children 2 to 4 years of age (n  1 to n  11; P 
0.042), and serotype 6C (n  12) was only detected PostVac within that age group
(Table S5).
MLST/CC. Among the 441 sequenced isolates, 41 CCs (29 CCs PreVac and 31 CCs
PostVac) and 86 STs (55 STs PreVac and 52 STs PostVac) were detected, and 7 CCs and
TABLE 2 Most common PNSP and MDR serotypes in nasopharyngeal samples PreVac (2009 to 2011) and PostVac (2012 to 2017)





P valuen % n % n % n %
19F 74 49.7 59 17.5 0.001 73 48.3 60 23.9 0.001
NESpb 34 22.8 85 25.1 0.657 35 23.2 85 33.9 0.025
6B 12 8.1 4 1.2 0.001 16 10.6 5 2.0 0.001
14 11 7.4 1 0.3 0.001 3 2.0 1 0.4 0.087
19A 6 4.0 35 10.4 0.021 3 2.0 9 3.6 0.516
6C 3 2.0 46 13.6 0.001 4 2.6 47 18.7 0.001
15A 0 0 29 8.6 0.001 0 0 29 11.6 0.001
23B 0 0 32 9.5 0.001 0 0 1 0.4 1.000
35B 0 0 25 7.1 0.001 0 0 0 0 NCc
Other PNSP/MDRd 9 6.0 22 6.5 1.000 4 2.6 6 2.4 1.000
Total 149 338 0.269 151 251 0.030
aPn, pneumococci.
bNESp, nonencapsulated S. pneumoniae.
cNC, not calculated.
dOther less prevalent serotypes of PNSP and MDR pneumococci.
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24 STs were unique to ME isolates. The STs of two isolates could not be determined as
a full-length allele was missing from the WGS data, but these isolates were members of
CC180 and CC236/271/320. The Simpson diversity indices of the STs were 0.91 PreVac
and 0.96 PostVac. A phylogenetic tree was created with the concatenated sequences of
1,250 full-length coding loci found in 99.8% of the ME pneumococcal genomes. The
tree was annotated with CC designations and serotypes (Fig. 2).
Fewer VT CCs were detected PostVac (6 CCs) than PreVac (18 CCs), and fewer STs
were detected within the CCs. Six STs of VT isolates were detected within CC43923F
PreVac, compared to only one ST PostVac (Fig. 2 and Table S6). CC236/271/32019F was
the most common CC in both study periods: 41.8% (115/275, 4.8/1,000 children) PreVac,
but it decreased in prevalence to 22.3% (37/166, 1.5/1,000 children) PostVac (P  0.001)
(Fig. 2 and Table S6). Between the periods, CC3156B/C increased from one serotype 6B
isolate to six serotype 6C isolates (P  0.05). CC126215B/C, CC19321, and CC181635B,
which contained NVTs, were only detected PostVac in ME samples, but CC126215B/C was
detected in low numbers in nasopharyngeal carriage PreVac. One isolate of NVT
serotype 23B PostVac belonged to CC156/1629V, a typically VT lineage (Fig. 2 and
Table S6).
Antimicrobial resistance. The overall prevalence of PNSP among ME isolates
decreased between the two study periods (48.1% versus 28.4%; P  0.001). The
TABLE 3 Serotype distribution each study year in ME samples among children 0 to 7 years old PreVac (2009 to 2011) and PostVac
(2012 to 2017)







(avg/yr) P value2009 2010 2011 2012 2013 2014 2015 2016 2017a PreVac
3 3 2 7 3 9 4 0 0 0 12 4.0 16 2.7 0.635
4 1 0 0 0 0 0 0 0 0 1 0.3 0 0 NCb
6A 14 22 11 13 12 2 1 1 0 47 15.7 29 4.8 0.159
6B 17 14 6 8 2 1 0 0 0 37 12.3 11 1.8 0.010
6C 0 0 1 2 10 10 7 8 4 1 0.3 41 6.8 0.001
9N 0 0 1 0 0 0 0 0 0 1 0.3 0 0 NC
9V 4 2 1 0 0 0 0 0 0 7 2.3 0 0 NC
10B 0 0 0 0 1 0 0 0 0 0 0 1 0.2 NC
11A 1 4 3 6 3 4 1 2 1 8 2.7 17 2.8 0.239
14 14 13 10 1 4 1 0 0 0 37 12.3 6 1.0 0.001
15A 0 0 0 0 1 1 0 1 3 0 0 6 1.0 NC
15B/C 2 2 1 15 22 2 5 8 1 5 1.7 53 8.8 0.001
16F 1 1 0 0 0 0 0 1 0 2 0.7 1 0.2 0.695
17 0 1 0 0 0 0 0 0 0 1 0.3 0 0 NC
18C 1 1 0 1 0 0 0 0 0 2 0.7 1 0.2 0.695
19F 85 69 88 33 27 5 0 2 0 242 80.7 67 11.2 0.001
19A 17 13 5 8 6 5 1 1 1 35 11.7 22 3.7 0.240
19C 1 0 0 0 0 0 0 0 0 1 0.3 0 0 NC
21 0 0 0 3 5 1 1 2 1 0 0 13 2.2 NC
22F 0 0 0 1 1 2 0 0 0 0 0 4 0.7 NC
23F 29 21 23 9 6 3 0 0 0 73 24.3 18 3.0 0.001
23A 1 1 0 2 5 1 8 6 1 2 0.7 23 3.8 0.003
23B 0 0 1 5 3 2 1 2 2 1 0.3 15 2.5 0.012
24F 0 0 1 0 0 0 0 2 0 1 0.3 2 0.3 0.707
33F 0 0 4 3 4 3 0 1 0 4 1.3 11 1.8 0.231
35F 0 1 0 0 3 0 1 0 0 1 0.3 4 0.7 0.365
35B 0 0 0 3 2 2 1 1 0 0 0 9 1.5 NC
38 1 0 1 0 0 0 0 0 0 2 0.7 0 0 NC
Other serotypesc 4 10 5 13 12 11 11 6 9 19 6.3 62 10.3 0.001
NESpd 1 0 0 1 0 0 0 0 0 1 0.3 1 0.2 0.995
Total 197 177 169 130 138 60 38 44 23 543 181 433 72.2 0.014
VTe 151 120 128 52 39 10 0 2 0 399 133.0 96 16.0 0.001
NVTf 46 57 41 78 99 50 38 42 23 144 49.0 337 56.2 0.001
All ME samples 966 926 951 849 894 687 505 452 421 2,843 947.7 3,808 634.7
Samples positive for Png (%) 20.4 19.1 17.8 15.3 15.4 8.7 7.5 9.7 5.5 19.1 11.4
aFrom 1 January to 30 September 2017.
bNC, not calculated.
cSerotypes other than those included in the multiplex PCR panel of the study.
dNESp, nonencapsulated S. pneumoniae.
eSerotypes detected in the study that are included in PHiD-CV (4, 6B, 9V, 14, 18C, 19F, and 23F).
fSerotypes detected in the study that are not included in PHiD-CV.
gPn, pneumococci.
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resistance to erythromycin decreased between the two periods (49.7% versus 29.8% of
isolates; P  0.001), and the prevalence of MDR pneumococci decreased also (49.2%
versus 29.8%; P  0.001). Before the introduction of PHiD-CV, 98.1% (56/261) of PNSP
were also MDR, and this was reduced to 91.9% (113/123; P  0.001). PNSP and MDR
isolates were mainly serotype 19F in both study periods (Table 4). Among the PNSP








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































FIG 2 Phylogenetic tree created from 1,250 full-length coding loci found in 99.8% of the 441 genomes from ME samples and annotated with CC designations.
Serotypes (inner circle) and the study periods (outer circle) are also presented.








valuen % n % n % n %
19F 231 88.6 66 53.7 0.001 232 86.9 65 50.4 0.001
6B 9 3.4 3 2.4 0.759 16 6.0 3 2.3 0.017
14 6 2.3 2 1.6 1.000 5 1.9 2 1.6 0.472
19A 4 1.5 9 7.3 0.006 2 0.7 9 7.0 0.014
23F 4 1.5 0 0 0.311 4 1.5 0 0 0.134
6C 0 0 19 15.4 0.001 0 0 30 23.3 0.001
15A 0 0 6 4.9 0.001 0 0 6 4.7 0.007
23B 1 0.4 5 4.1 0.014 1 0.4 1 0.8 1.000
Other PNSP/MDR Pnb 6 2.3 13 10.6 0.001 7 2.6 13 10.1 0.040
Total 261 123 0.001 267 129 0.001
aPn, pneumococci.
bOther less prevalent serotypes of PNSP and MDR pneumococci.
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serotype 6C amounted to 15.4% of PNSP (P  0.001) and 23.3% of MDR pneumococci
(P  0.001) detected PostVac (Table 4). The serotype 6C PNSP/MDR isolates were not
detected before vaccine implementation and were members of CC3156B,6C.
Serotype 19A PNSP increased from 1.5% to 7.3% (P  0.006), and MDR serotype 19A
increased from 0.7% to 7.0% (P  0.014) (Table 4). Serotype 19A PNSP/MDR pneumo-
cocci were members of various CCs (Fig. 2 and Table S6). NVT PNSP with serotypes 15A
and 23B also increased after vaccine introduction, and they were members of CC6315A
and CC33823B, respectively. NVT serotype 15A PNSP (also MDR) was only detected after
vaccination in ME isolates (Table 4, Fig. 2, and Table S6).
Comparison of serotypes in nasopharyngeal isolates from carriage and ME
isolates from children with AOM 1 to <4 years of age. Overall, 2,291 pneumococcal
isolates were obtained from children 1 to 4 years of age: 1,457 isolates from
nasopharyngeal samples from carriage (n  493 PreVac and n  964 PostVac) and 834
isolates from AOM ME samples (n  467 PreVac and n  367 PostVac).
The same serotypes were among the most prevalent serotypes PreVac in both
sample groups, and the levels of serotype replacement PostVac were similar in both
groups (Table 5, Fig. 3). One isolate of VT serotype 23F was detected in carriage among
children 1 to 4 years of age in 2017, and no VTs were detected in children with AOM
within the same age group after 2016. Serotype 6A decreased slightly PostVac among
children with AOM but not in carriage (P  0.050) (Fig. 3). Serotypes 6C, 15B/C, 23A, and
23B increased (Fig. 3).
VT serotype 19F was more frequently found in AOM than in carriage in children 1 to
4 years of age in both study periods: 32.1% (268/834) of ME isolates were serotype
19F compared to 7.2% (105/1,457) of carriage isolates (P  0.001). The NVT serotype
23B was more frequently found in carriage than in AOM in children 1 to 4 years of
age: 5.0% (73/1,457) of carriage isolates were serotype 23B compared to only 1.7%
(14/834) of the ME isolates (P  0.006). Serotype 6C was prevalent in both carriage and
AOM among children 1 to 4 years of age, but MDR was more common in ME isolates
(P  0.001). NESp isolates were more frequently found in carriage than among children
with AOM in both study periods (P  0.001) (Table 5).
TABLE 5 The most common VTs and NVTs in carriage and ME samples from children 1 to 4 years old PreVac (2009 to 2011) and
PostVac (2012 to 2017)























6A 48 9.7 43 9.2 0.766 76 7.9 28 7.6 0.889
6B 63 12.8 33 7.1 0.003 37 3.8 10 2.7 0.332
6C 6 1.2 0 0 0.018 90 9.3 36 9.8 0.696
11A 25 5.1 6 1.3 0.001 64 6.6 15 4.1 0.074
15B/C 13 2.6 2 0.4 0.005 88 9.1 47 12.8 0.051
19F 63 12.8 215 46.0 0.001 43 4.5 53 14.4 0.001
19A 44 8.9 27 5.8 0.061 67 7.0 17 4.6 0.117
23F 67 13.6 65 13.9 0.830 45 4.7 17 4.6 0.993
23A 16 3.2 1 0.2 0.001 70 7.3 19 5.2 0.172
23B 1 0.2 1 0.2 0.975 72 7.5 13 3.5 0.006
Less prevalent serotypes 111 22.5 73 15.6 NCa 255 26.5 111 30.2 NC
NESpb 36 7.3 1 0.2 0.001 59 6.1 1 0.3 0.001
Total 493 100 467 100 NC 964 100 367 100 NC
VTc 256 51.9 353 75.6 0.001 141 14.6 87 23.7 0.001
NVTd 237 48.1 114 24.4 0.001 823 85.4 280 76.3 0.001
aNC, not calculated.
bNESp, nonencapsulated S. pneumoniae.
cSerotypes detected in the study that are included in PHiD-CV (4, 6B, 9V, 14, 18C, 19F, and 23F).
dSerotypes detected in the study that are not included in PHiD-CV.
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This study shows a significant reduction of VTs in nasopharyngeal carriage of
healthy children and in ME samples in children 7 years old 6 years after PHiD-CV
implementation in Iceland. The total number of pneumococci isolated from the naso-
pharynges of children remained unchanged after vaccination due to serotype replace-
ment by NVTs; however, at the same time, the total number of ME isolates decreased
significantly. The ME samples in our study were most often from children with ruptured
tympanic membranes as a consequence of AOM or from children with tympanic tubes
and discharge from the middle ear as a consequence of inflammation in the middle ear.
Consequently, we postulate that the decrease in the number of samples from the ME
most likely reflects a decrease in the burden of AOM (52). Certain serotypes are
associated with nasopharyngeal carriage in healthy children, while others are more
prone to cause disease (53, 54); however, the NVTs that have replaced the VTs following
routine vaccination may, to a great extent, express a low invasive disease potential (55).
It was confirmed in our study that the distribution of serotypes and genetic lineages
in nasopharyngeal carriage in children reflected those identified from the discharges
from ears of children with AOM (56). Furthermore, the diversity of the pneumococcal
STs did not change between the periods.
The same serotypes and genetic lineages were often found in nasopharyngeal and
ME samples in children 1 to 4 years of age, both PreVac and PostVac but often in
different proportions. There was a slight but significant decrease in serotype 6A among
children with AOM, which has been described in IPD among all ages following PHiD-CV
vaccination (57). Serotypes 6C, 23A, and 23B were not affected by the vaccination, as
these serotypes increased significantly in both sample groups, which has also been
documented elsewhere (21, 58–62).
Serotype 19F was particularly “otogenic,” as it was four times more prevalent in ME
samples than in nasopharyngeal samples. The main serotype 19F in CC236/270/32019F
harbors genes for pili (both PI-1 and PI-2), which likely contributed to the adherence to
the mucosa of the middle ear (63). Serotype 6B had a preference for nasopharyngeal
FIG 3 The annual average numbers of the most prevalent serotypes and NESp isolates detected in carriage versus ME samples
among children 1 4 years of age PreVac (2009 to 2011) and PostVac (2012 to 2017). , decreased significantly between the
two study periods; *, increased significantly between the two study periods; Nc, not calculated; NESp, nonencapsulated S.
pneumoniae.
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colonization PreVac, while the same was true for serotype 23B PostVac. This finding is
in concordance with other reports where serotype 23B was associated with persistent
carriage and posed a lower risk for IPD (55, 64).
The NESp isolates were largely associated with carriage in both study periods but
extremely rare in AOM. However, while the prevalence of NESp did not change
significantly after vaccination in carriage, MDR among NESp isolates increased signifi-
cantly.
In our study, only one VT isolate was detected between 2014 and 2016 in ME
samples among children 1 to 4 years of age, whereas 11 VT isolates were detected
between 2014 and 2017 in the nasopharynges of healthy children of the same ages.
This indicates that PHiD-CV may be more effective in preventing AOM (measured as
fewer positive ME samples) than in preventing nasopharyngeal carriage. This is impor-
tant, as AOM caused by pneumococci is more severe than that caused by other
common pathogens (65, 66).
The increase of the MDR serotype 6C isolates PostVac in both nasopharynx and ME
samples is of concern. Other researchers have also described an increase in serotype 6C
following the introduction of PCV7, especially in non-IPD among children (67). We
rarely detected isolates of serotype 6C PreVac; however, in a recent study, serotype 6C
was only detected among vaccinated children with non-IPD after PHiD-CV implemen-
tation (68). Serotype 6C isolates detected PostVac most often belonged to CC3156B and
ST3866C (a double locus variant [DLV] of PMEN Poland6B-20). The MDR ST3866C was
detected in Spain 6 years after PCV7 implementation (69), and other countries have also
reported the emergence of this lineage in nasopharyngeal carriage and IPD following
the implementation of PHiD-CV (62). This lineage might be derived from a capsular
switch from serotype 6B to serotype 6C, as has previously been reported by our group
(36).
The majority of serotype 23B isolates belonged to CC439/ST43923B (single locus
variant [SLV] of PMEN Tennessee23F-4); however, this lineage was only detected PostVac
in both sample groups in our study. CC439/ST43923B was present, although uncom-
mon, in Germany prior to the implementation of vaccinations but increased after
vaccine implementation. This lineage has also been documented in other countries
worldwide (70).
One ME isolate of serotype 23B belonged to CC156/162 and ST162 (an SLV of PMEN
Spain9V-3). This was the only isolate of this lineage detected PostVac in ME isolates.
Serotype switch variants of the related ST156 expressing serotypes 9V, 9A, 14, 19F, and
11A have also been reported (71). Pneumococci have the ability to change their
capsular serotype by exchanging the capsular locus genes (72). The expansion of
preexisting lineages and their variants, such as CC3156B/C and CC43923F/B, may be more
likely following PCV vaccination than the emergence of new lineages (70).
Iceland offers a unique opportunity for researching vaccine effects for several
reasons. The reference laboratory at the Department of Clinical Microbiology, Landspi-
tali University Hospital, serves approximately 85% of the country for pneumococcus-
positive samples and stores all isolates (at 80°C). Furthermore, carriage studies have
been conducted within the same DCCs using the same methodology throughout the
study period. PCVs were not part of the routine infant immunization program before
PHiD-CV implementation in 2011. Since then, vaccine acceptance and the uptake of
PCVs have been high (73, 74). In our study, we analyzed a large number of pneumo-
coccal isolates representative of the Icelandic population. Furthermore, one third of the
pneumococcal isolates were subjected to WGS, which gives a good overview of the
composition of genetic lineages in the country. However, fluctuations in serotypes and
genotypes are known among pneumococci, even without the selective pressure of
PCVs (75, 76).
In conclusion, PHiD-CV implementation eliminated VTs in the MEs of children with
otitis media within 5 years. The carriage rate of pneumococci in healthy children
remained constant between the periods due to serotype replacement of NVTs, but the
total number of ME isolates decreased significantly PostVac. Serotype 23B and NESp
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had a preference for nasopharyngeal carriage among children 1 to 4 years of age.
Multidrug resistance among serotype 6C was more common in ME samples among
children 1 to 4 years of age than in nasopharyngeal carriage samples PostVac.
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